{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T01:06:23Z","timestamp":1794877583954,"version":"4.9.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Inhibition of poly(ADP-ribose) polymerase (PARP) after relapse on hormone therapy is well established for patients with prostate cancer with homologous recombination repair (HRR) gene alterations, but resistance often develops. We hypothesized that PARP inhibition within 6\u2009months of starting androgen deprivation therapy for metastatic castration-sensitive prostate cancer (mCSPC) could be effective and improve radiographic progression-free survival when added to standard-of-care treatments. The double-blind AMPLITUDE trial evaluated combining niraparib, a potent and specific PARP inhibitor, with abiraterone acetate and prednisone (AAP) versus placebo and AAP in mCSPC with HRR gene alterations. Patients (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009696) were randomized in a 1:1 ratio (348 per group). Median age was 68\u2009years; 56% had\n                    <jats:italic>BRCA1<\/jats:italic>\n                    or\n                    <jats:italic>BRCA2<\/jats:italic>\n                    alterations; 78% had high-volume metastases; and 16% had received docetaxel. The primary endpoint was met, with a significant improvement in radiographic progression-free survival observed first in the BRCA subgroup (median not reached at the time of analysis for the niraparib and AAP group versus 26\u2009months for the AAP group; hazard ratio\u2009=\u20090.52; 95% confidence interval: 0.37\u20130.72;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.0001) and then in the intention-to-treat population (hazard ratio\u2009=\u20090.63; 95% confidence interval: 0.49\u20130.80;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0001). The data for overall survival, a key secondary endpoint, are immature (193\/389 events) but favor niraparib (hazard ratio\u2009=\u20090.79 (95% confidence interval: 0.59\u20131.04); BRCA subgroup: hazard ratio\u2009=\u20090.75 (95% confidence interval: 0.51\u20131.11)). Incidence of grade 3 or 4 adverse events was 75% in the niraparib and AAP group and 59% in the AAP group; most frequent in the niraparib and AAP group were anemia (29%), with 25% of patients requiring a blood transfusion, and hypertension (27%). There were 14 treatment-emergent adverse events leading to deaths in the niraparib group and seven in the placebo group. Combining niraparib with AAP significantly improved radiographic progression-free survival in patients with mCSPC harboring\n                    <jats:italic>BRCA1\/BRCA2<\/jats:italic>\n                    or other HRR gene alterations, suggesting clinical benefit with this combination for these patients. ClinicalTrials.gov identifier:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\/study\/NCT04497844\" ext-link-type=\"uri\">NCT04497844<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-025-03961-8","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T09:04:08Z","timestamp":1759827848000},"page":"4109-4118","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4811-7983","authenticated-orcid":false,"given":"Gerhardt","family":"Attard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1076-0428","authenticated-orcid":false,"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5708-2794","authenticated-orcid":false,"given":"Julie N.","family":"Graff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8660-4475","authenticated-orcid":false,"given":"Shahneen","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Efstathiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8417-8628","authenticated-orcid":false,"given":"Mustafa","family":"\u00d6zg\u00fcro\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7388-663X","authenticated-orcid":false,"given":"Andrea J.","family":"Pereira de Santana Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4864-7183","authenticated-orcid":false,"given":"Karina","family":"Vianna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey T.","family":"Gotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather H.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly R.","family":"Varela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daneen","family":"Schaeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kassie","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5494-4475","authenticated-orcid":false,"given":"Fei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suneel D.","family":"Mundle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon A.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Olmos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim N.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana E.","family":"Rathkopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"3961_CR1","doi-asserted-by":"publisher","first-page":"5717","DOI":"10.1016\/j.cell.2025.07.042","volume":"188","author":"E Grist","year":"2025","unstructured":"Grist, E. et al. Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers. Cell 188, 5717\u20135734 (2025).","journal-title":"Cell"},{"key":"3961_CR2","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James, N. D. et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N. Engl. J. Med. 377, 338\u2013351 (2017).","journal-title":"N. Engl. J. Med."},{"key":"3961_CR3","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi, K. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 377, 352\u2013360 (2017).","journal-title":"N. Engl. J. Med."},{"key":"3961_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi, K. N. et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 381, 13\u201324 (2019).","journal-title":"N. Engl. J. Med."},{"key":"3961_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis, I. D. et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N. Engl. J. Med. 381, 121\u2013131 (2019).","journal-title":"N. Engl. J. Med."},{"key":"3961_CR6","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S1470-2045(23)00148-1","volume":"24","author":"G Attard","year":"2023","unstructured":"Attard, G. et al. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol. Lancet Oncol. 24, 443\u2013456 (2023).","journal-title":"Lancet Oncol."},{"key":"3961_CR7","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215\u20131228 (2015).","journal-title":"Cell"},{"key":"3961_CR8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard, C. C. et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N. Engl. J. Med. 375, 443\u2013453 (2016).","journal-title":"N. Engl. J. Med."},{"key":"3961_CR9","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1200\/JCO.18.00358","volume":"37","author":"E Castro","year":"2019","unstructured":"Castro, E. et al. PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol. 37, 490\u2013503 (2019).","journal-title":"J. Clin. Oncol."},{"key":"3961_CR10","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.annonc.2024.01.011","volume":"35","author":"D Olmos","year":"2024","unstructured":"Olmos, D. et al. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes. Ann. Oncol. 35, 458\u2013472 (2024).","journal-title":"Ann. Oncol."},{"key":"3961_CR11","doi-asserted-by":"crossref","unstructured":"Olmos, D. et al. BRCA1\/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes. Ann Oncol. 36, 1190\u20131202 (2025).","DOI":"10.1016\/j.annonc.2025.05.534"},{"key":"3961_CR12","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917\u2013921 (2005).","journal-title":"Nature"},{"key":"3961_CR13","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913\u2013917 (2005).","journal-title":"Nature"},{"key":"3961_CR14","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","volume":"383","author":"M Hussain","year":"2020","unstructured":"Hussain, M. et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N. Engl. J. Med. 383, 2345\u20132357 (2020).","journal-title":"N. Engl. J. Med."},{"key":"3961_CR15","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","volume":"388","author":"K Fizazi","year":"2023","unstructured":"Fizazi, K. et al. Rucaparib or physician\u2019s choice in metastatic prostate cancer. N. Engl. J. Med. 388, 719\u2013732 (2023).","journal-title":"N. Engl. J. Med."},{"key":"3961_CR16","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","volume":"30","author":"K Fizazi","year":"2024","unstructured":"Fizazi, K. et al. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat. Med. 30, 257\u2013264 (2024).","journal-title":"Nat. Med."},{"key":"3961_CR17","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1200\/JCO.22.01649","volume":"41","author":"KN Chi","year":"2023","unstructured":"Chi, K. N. et al. Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer. J. Clin. Oncol. 41, 3339\u20133351 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3961_CR18","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","volume":"34","author":"KN Chi","year":"2023","unstructured":"Chi, K. N. et al. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann. Oncol. 34, 772\u2013782 (2023).","journal-title":"Ann. Oncol."},{"key":"3961_CR19","doi-asserted-by":"crossref","unstructured":"Chi, K. N. et al. Niraparib and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: final overall survival analysis for the phase 3 MAGNITUDE trial. Eur. Urol. Oncol. 8, 986\u2013998 (2025).","DOI":"10.1016\/j.euo.2025.04.012"},{"key":"3961_CR20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","volume":"402","author":"N Agarwal","year":"2023","unstructured":"Agarwal, N. et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet 402, 291\u2013303 (2023).","journal-title":"Lancet"},{"key":"3961_CR21","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","volume":"24","author":"F Saad","year":"2023","unstructured":"Saad, F. et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 24, 1094\u20131108 (2023).","journal-title":"Lancet Oncol."},{"key":"3961_CR22","doi-asserted-by":"crossref","unstructured":"Mateo, J. et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 21, 162\u2013174 (2020).","DOI":"10.1016\/S1470-2045(19)30684-9"},{"key":"3961_CR23","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo, J. et al. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med. 373, 1697\u20131708 (2015).","journal-title":"N. Engl. J. Med."},{"key":"3961_CR24","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1200\/JCO.23.02105","volume":"42","author":"J Fallah","year":"2024","unstructured":"Fallah, J. et al. Efficacy of poly(ADP-ribose) polymerase inhibitors by individual genes in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer: a US Food and Drug Administration pooled analysis. J. Clin. Oncol. 42, 1687\u20131698 (2024).","journal-title":"J. Clin. Oncol."},{"key":"3961_CR25","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S1470-2045(21)00757-9","volume":"23","author":"MR Smith","year":"2022","unstructured":"Smith, M. R. et al. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. Lancet Oncol. 23, 362\u2013373 (2022).","journal-title":"Lancet Oncol."},{"key":"3961_CR26","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1158\/2159-8290.CD-17-0146","volume":"7","author":"D Quigley","year":"2017","unstructured":"Quigley, D. et al. Analysis of circulating cell-free DNA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors. Cancer Discov. 7, 999\u20131005 (2017).","journal-title":"Cancer Discov."},{"key":"3961_CR27","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/j.ccell.2024.10.015","volume":"42","author":"G Seed","year":"2024","unstructured":"Seed, G. et al. Elucidating acquired PARP inhibitor resistance in advanced prostate cancer. Cancer Cell 42, 2113\u20132123 (2024).","journal-title":"Cancer Cell"},{"key":"3961_CR28","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1158\/2159-8290.CD-13-0172","volume":"3","author":"WR Polkinghorn","year":"2013","unstructured":"Polkinghorn, W. R. et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov. 3, 1245\u20131253 (2013).","journal-title":"Cancer Discov."},{"key":"3961_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00393-y","volume":"8","author":"M Asim","year":"2017","unstructured":"Asim, M. et al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat. Commun. 8, 374 (2017).","journal-title":"Nat. Commun."},{"key":"3961_CR30","doi-asserted-by":"publisher","first-page":"eaam7479","DOI":"10.1126\/scisignal.aam7479","volume":"10","author":"L Li","year":"2017","unstructured":"Li, L. et al. Androgen receptor inhibitor-induced \u2018BRCAness\u2019 and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci. Signal. 10, eaam7479 (2017).","journal-title":"Sci. Signal."},{"key":"3961_CR31","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore, K. et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 379, 2495\u20132505 (2018).","journal-title":"N. Engl. J. Med."},{"key":"3961_CR32","unstructured":"AKEEGA. Prescribing Information. (Janssen Biotech, Inc.; 2023)."},{"key":"3961_CR33","unstructured":"AKEEGA. Product information. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/akeega-epar-product-information_en.pdf (accessed 22 September 2025)."},{"key":"3961_CR34","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong, A. J. et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J. Clin. Oncol. 37, 2974\u20132986 (2019).","journal-title":"J. Clin. Oncol."},{"key":"3961_CR35","doi-asserted-by":"publisher","first-page":"TPS221","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS221","volume":"40","author":"N Agarwal","year":"2022","unstructured":"Agarwal, N. et al. TALAPRO-3: a phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus enza in patients with DDR gene mutated metastatic castration-sensitive prostate cancer. J. Clin. Oncol. 40, TPS221 (2022).","journal-title":"J. Clin. Oncol."},{"key":"3961_CR36","doi-asserted-by":"publisher","first-page":"TPS178","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS178","volume":"39","author":"K Fizazi","year":"2021","unstructured":"Fizazi, K. et al. A phase III trial of capivasertib and abiraterone versus placebo and abiraterone in patients with de novo metastatic hormone-sensitive prostate cancer characterized by PTEN deficiency (CAPItello-281). J. Clin. Oncol. 39, TPS178 (2021).","journal-title":"J. Clin. Oncol."},{"key":"3961_CR37","doi-asserted-by":"publisher","first-page":"S993","DOI":"10.1016\/j.annonc.2023.09.2783","volume":"34","author":"S Sandhu","year":"2023","unstructured":"Sandhu, S. et al. A prospective study to determine the prevalence of DNA repair defects in patients (pts) with advanced prostate cancer (PC). Ann. Oncol. 34, S993 (2023).","journal-title":"Ann. Oncol."},{"key":"3961_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00280-021-04249-7","volume":"88","author":"F Saad","year":"2021","unstructured":"Saad, F. et al. Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE). Cancer Chemother. Pharmacol. 88, 25\u201337 (2021).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"3961_CR39","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","volume":"20","author":"CJ LaFargue","year":"2019","unstructured":"LaFargue, C. J., Dal Molin, G. Z., Sood, A. K. & Coleman, R. L. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 20, e15\u2013e28 (2019).","journal-title":"Lancet Oncol."},{"key":"3961_CR40","doi-asserted-by":"publisher","first-page":"103984","DOI":"10.1016\/j.esmoop.2024.103984","volume":"9","author":"V Tuninetti","year":"2024","unstructured":"Tuninetti, V., Marin-Jimenez, J. A., Valabrega, G. & Ghisoni, E. Long-term outcomes of PARP inhibitors in ovarian cancer: survival, adverse events, and post-progression insights. ESMO Open 9, 103984 (2024).","journal-title":"ESMO Open"},{"key":"3961_CR41","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","volume":"87","author":"S Gillessen","year":"2025","unstructured":"Gillessen, S. et al. Management of patients with advanced prostate cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). Eur. Urol. 87, 157\u2013216 (2025).","journal-title":"Eur. Urol."},{"key":"3961_CR42","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1200\/JCO.22.00208","volume":"40","author":"M Hussain","year":"2022","unstructured":"Hussain, M. et al. Evolving role of prostate-specific membrane antigen-positron emission tomography in metastatic hormone-sensitive prostate cancer: more questions than answers?. J. Clin. Oncol. 40, 3011\u20133014 (2022).","journal-title":"J. Clin. Oncol."},{"key":"3961_CR43","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney, C. J. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 373, 737\u2013746 (2015).","journal-title":"N. Engl. J. Med."},{"key":"3961_CR44","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher, H. I. et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J. Clin. Oncol. 34, 1402\u20131418 (2016).","journal-title":"J. Clin. Oncol."},{"key":"3961_CR45","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/j.1524-4733.2008.00409.x","volume":"12","author":"D Cella","year":"2009","unstructured":"Cella, D., Nichol, M. B., Eton, D., Nelson, J. B. & Mulani, P. Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy\u2013Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value Health 12, 124\u2013129 (2009).","journal-title":"Value Health"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03961-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03961-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03961-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T15:59:45Z","timestamp":1765814385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03961-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3961"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03961-8","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"1 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.A. reports consulting\/advisory roles with Amgen, AstraZeneca, Astellas Pharma, Bayer, Blue Earth Therapeutics, Janssen-Cilag, Merck & Co, Merck Sorono Ltd., Novartis, Pfizer and Veracyte; honoraria from Astellas Pharma, Janssen and Janssen (for an immediate family member); speaker\u2019s bureau with AstraZeneca, Astellas Pharma, Janssen, Sanofi and Sandoz; grants\/research funding from Astellas Pharma, Blue Earth Therapeutics, Janssen and Novartis; travel, accommodations and expenses from Amgen, Astellas Pharma, Astellas Pharma (for an immediate family member), Bayer, Bristol Myers Squibb (for an immediate family member), Janssen, Janssen (for an immediate family member), Merck Sorono Ltd. and Pfizer; and patents, royalties or other intellectual property as on the Institute of Cancer Research discoverers\u2019 list of abiraterone acetate. N.A. reports institutional grant\/research funding from Amgen, Arvinas, AstraZeneca, Bayer, Bristol Myers Squibb, Calithera Biosciences, Celldex, CRISPR Therapeutics, Eisai, Exelixis, Genentech, Gilead Sciences, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals and Pfizer and travel reimbursement from Exelixis and Pfizer. J.N.G. reports research funding from Curium Pharma, Janssen Oncology and Merck and patents, royalties or other intellectual property from OncoResponse: exceptional responders. S.S. reports consulting\/advisory roles with AbbVie, AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Roche\/Genentech, Janssen, AdvanCell and Skyline Diagnostics; honoraria to the institution from AbbVie, AstraZeneca, Bristol Myers Squibb, Janssen, Merck, Merck Serono, Novartis, AdvanCell and Skyline Diagnostics; institutional research funding from Amgen, AstraZeneca, Bristol Myers Squibb, Endocyte\/Advanced Accelerator Applications, Genentech\/Roche, Merck, Novartis, Pfizer and Senhwa Biosciences; and stock ownership in AdvanCell. E.E. reports honoraria from AstraZeneca, Bayer, Myovant Sciences, Pfizer and Sumitomo; consulting\/advisory roles with Astellas Pharma, AstraZeneca, Johnson & Johnson, Merck, Pfizer and Tolmar; and research funding from Astellas Pharma, AstraZeneca, Johnson & Johnson, Merck and Pfizer. M.\u00d6. reports consulting\/advisory roles with Astellas Pharma, AstraZeneca and MSD Oncology; honoraria from Astellas Pharma, Janssen Oncology and Novartis; and speaker\u2019s bureau role and travel expenses from AstraZeneca. A.G. reports consulting\/advisory roles with Bayer and Janssen Oncology; speaker\u2019s bureau roles with Astellas Pharma, AstraZeneca, Bayer and Janssen Oncology; honoraria from Adium Pharma, Astellas Pharma, AstraZeneca, Bayer and Janssen Oncology; research funding from AstraZeneca, Bayer, Janssen Oncology, MSD Oncology and Roche; and travel expenses from Janssen Oncology. K.V. reports consulting\/advisory roles with Adium Pharma, AstraZeneca and Roche\/Genentech; speaker\u2019s bureau roles with AstraZeneca, Bayer, Bristol Myers Squibb Brazil, GlaxoSmithKline, Knight Pharmaceuticals, Pfizer, Roche\/Genentech and Servier; institutional research funding from AstraZeneca, BeiGene, Bristol Myers Squibb Brazil, Gilead Sciences, Incyte, Janssen Oncology, Lilly, MSD Oncology, Roche\/Genentech, Seagen and Servier; and travel expenses from AstraZeneca, MSD Oncology and Roche\/Genentech. H.L. has no conflicts of interest to report. G.T.G. reports consulting\/advisory roles with Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, EMD Serono, Ferring, Janssen, Merck, Novartis, Pfizer and Tolmar; honoraria from Astellas Pharma, AstraZeneca, Bayer, Janssen, Merck and Tolmar; and travel expenses from Janssen and Pfizer. H.H.C. reports a consulting\/advisory role with Janssen Oncology; institutional research funding from Clovis Oncology, Janssen, Promontory Therapeutics and Sanofi; and royalties from UpToDate. W.K., C.R.V., D.S., K.K., S.L., B.B., F.S., S.D.M. and S.A.M. are employees of Johnson & Johnson with stock ownership. D.O. reports consulting\/advisory roles with AstraZeneca, Bayer, Janssen, MSD Oncology and Pfizer; honoraria from Bayer and Janssen; institutional research funding from Johnson & Johnson\/Janssen and Pfizer; travel expenses from AstraZeneca Spain, Bayer and Janssen; and stock ownership in VDG Diagnostics. K.N.C. reports consulting\/advisory roles with Amgen, Astellas Pharma, AstraZeneca, Bayer, BMS GmbH & Co. KG, Janssen, Merck, POINT Biopharma and Roche; honoraria from Amgen, Astellas Pharma, AstraZeneca, Bayer, BMS GmbH & Co. KG, Janssen, Merck, Novartis, POINT Biopharma, Roche and Pfizer; and institutional research funding from Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, ESSA, Janssen, Merck, Novartis, Pfizer and Roche. D.E.R. reports consulting\/advisory roles with Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb\/Celgene, Curium, Genentech, Janssen, Myovant Sciences, Novartis and Promontory Therapeutics and institutional research funding from AstraZeneca, Bristol Myers Squibb\/Celgene, Genentech\/Roche, Janssen Oncology, Novartis and Promontory Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}